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gastrointestinal (GI) tract (constipation, fecaloma) were re-
ported with both immediate-release (IR) and extended-
release (ER) formulations of opioids versus placebo: IR opi-
oids (relative risk [RR] = 5.20, 95% confidence interval [CI]
3.42, 7.89); ER opioids (RR = 4.22, 95% CI 3.44, 5.17). The
risk of risk of nausea, vomiting or loss of appetite increased 4
to 5-fold with both IR (RR = 3.39, 95% CI 2.22, 5.18) and ER
opioids (RR = 4.03, 95% CI 3.37, 4.83). An increased risk of
dermatologic AEs (rash and pruritis) (IR opioids: RR = 3.60,
95% CI 1.74, 7.43; ER opioids: RR = 7.87, 95% CI, 5.20,
11.89). For COX-2 inhibitors, database searches identified
2149 records from which, after exclusions, 40 trials were in-
cluded in the meta-analysis. The use of COX-2 inhibitors in
OAwas associated with a significantly increased risk of drug-
related AEs compared with placebo (relative risk [RR] = 1.26,
95% CI 1.09, 1.46; I2 = 24%). The risk of upper gastrointes-
tinal complications (including dyspepsia, gastritis, and heart-
burn) was significantly increased with COX-2 inhibitors ver-
sus placebo (RR = 1.19, 95% CI 1.03, 1.38; I2 = 0%). The risk
of heart failure and edema was increased by nearly 70% with
COX-2 inhibitors versus placebo (RR = 1.68, 95% CI 1.22,
2.31; 0%).
Conclusions: Our results confirm the concerns regarding
safety and tolerability surrounding the use of opioids and
COX-2 inhibitors in OA.
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Objectives: In the absence of any treatments clearly
established to modify the progression of OA, a number
of products have been tested and/or promulgated for po-
tential chondroprotective effects while providing symp-
tom relief. These treatments could theoretically be prefer-
able to traditional analgesic regimens through lower risk
of toxicity. We comprehensively assessed the safety pro-
files of agents in this broad category in patients with knee
and/or hip OA.
Material and methods: We searched Medline and the
Cochrane Databases from inception through December
2017. We included randomized controlled trials (RCTs) of
knee / hip OA that tested avocado soybean unsaponifiables
(ASU), glucosamine (GC), chondroitin (CS), risedronate, cal-
citonin, diacerein strontium ranelate (SR), intra-articular
hyaluronic acid (IAHA), intra-articular corticosteroids
(IACS). Reference screening and extraction of adverse event
data were undertaken by two independent reviewers. We cal-
culated risk ratios and 95% confidence intervals using a ran-
dom effects model. Data from knee OA, hip OA, and mixed
knee/hip OA populations were analyzed separately.
Results: We identified 118 eligible RCTs involving
22,994 knee OA patients, 18 RCTs involving 1877 hip
OA patients, and 2 RCTs involving 468 patients with
knee and/or hip OA. In these RCTS, there were no sig-
nificant increase in risk for adverse events compared to
placebo for ASU, GC, CS, risedronate, or SR. Evidence
of toxicity was evident in RCTs of calcitonin (more with-
drawals, GI AEs, flushes); diacerein (diarrhea, with-
drawals), IAHA (AEs, SAEs, and local reactions). There
was no significant difference in safety outcomes observed
between IACS and IA placebo in studies of up to 2 years,
although one of these detected an increased rate of carti-
lage damage of uncertain clinical significance. Quality of
toxicity reporting was generally low and in one instance
inconsistent with post-marketing surveillance (SR).
Conclusions: Evaluation of toxicity profiles based on
RCTs can be limited by methodologic problems, incon-
sistent reporting, small numbers of events (especially se-
rious events) and issues of generalizability. However, no
safety signals emerged for nutritional products promul-
gated for OA.
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The European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) published a
treatment algorithm for the management of knee osteo-
arthritis (OA) in 2014, which provides practical guid-
ance for the prioritization of interventions. Basic principles
consist of the need for a combined pharmacological and non-
pharmacological treatment with a core set of initial measures,
including information access/education, weight loss if over-
weight, and an appropriate exercise program. Four multimod-
al steps are then established. Step 1 consists of background
therapy, either non-pharmacological (referral to a physical
therapist for re-alignment treatment if needed and sequential
introduction of further physical interventions initially and at
any time thereafter) or pharmacological. The latter consists of
chronic Symptomatic Slow-Acting Drugs for OA (e.g., pre-
scription glucosamine sulfate and/or chondroitin sulfate) with
paracetamol at-need; topical NSAIDs are added in the still
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symptomatic patient. Step 2 consists of the advanced pharma-
cological management in the persistent symptomatic patient
and is centred on the use of oral COX-2 selective or non-
selective NSAIDs, chosen based on concomitant risk factors,
with intra-articular corticosteroids or hyaluronate for further
symptom relief if insufficient. In Step 3, the last pharmaco-
logical attempts before surgery are represented by weak
opioids and other central analgesics. Finally, Step 4 con-
sists of end-stage disease management and surgery, with
classical opioids as a difficult-to-manage alternative when
surgery is contraindicated. Further analysis of real-world
data for OA, published in 2016, provided additional evi-
dence in support of pharmacological interventions, in
terms of management of OA pain and function, avoidance
of adverse events, disease-modifying effects and long-
term outcomes, e.g., delay of total joint replacement sur-
gery, and pharmacoeconomic factors such as reduction in
healthcare resource utilization. Since 2014, these guidance
documents have received international endorsement, with
translation, adaptation to the local context, and publica-
tion in China, Russia, and South-East Asia.
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Knee osteoarthritis (OA) affects around 4% of people world-
wide and accounts for 17.1 million years of life lived with
disability. It is expected to become the fourth leading cause
of functional impairment by 2020, placing a huge burden on
health services. Recommendations for the management of
knee OA have been issued by several international and nation-
al bodies, including the European League Against
Rheumatism (EULAR); the American Society for
Rheumatology (ACR); and the Osteoarthritis Research
Society (OARSI). These have recently been systematically
evaluated by the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis
(ESCEO), to construct a treatment algorithm that might en-
hance OA management throughout Europe and worldwide.
The initiative advanced existing practice guidelines, which
typically evaluate interventions individually, by prioritizing
these into a well- ordered series of practical steps which can
be undertaken by physicians. The algorithm was constructed
by an international taskforce experienced in the performance,
analysis and interpretation of clinical trial evidence in OA.
The core set of measures, which are applicable to all patients
with knee OA include: (a) Access to information about the
disease and education about the disorder; (b) Weight loss if
adipose; and provision of (c) an exercise programme. The
consequent treatment algorithm consists of four multimodal
steps. Step 1 consists of background therapy, either non-
pharmacological (referral to a physical therapist for realign-
ment treatment if needed and sequential introduction of fur-
ther physical interventions) or pharmacological. The latter
consists of chronic symptomatic slow-acting drugs for OA
(eg prescription of glucosamine sulphate with chondroitin sul-
phate) with paracetamol if required; topical NSAIDs are
added in the still symptomatic patient. Step 2 consists of the
advanced pharmacological management in the persistently
symptomatic patient. It centres on the use of oral COX-2 se-
lective or non-selective NSAIDs, chosen based o concomitant
risk factors, with intra-articular glucocorticoids or hyaluronic
acid derivatives for further symptom relief. Step 3 incorpo-
rates the remaining pre-surgical pharmacological measures
including weak opioids and other central analgesics
such as duloxetine; Step 4 progresses to surgical inter-
vention, or classical opioids where surgery is contrain-
dicated. This treatment algorithm represents a new
framework for the development of future guidelines for
OA management, which are more easily accessible to
primary and secondary care physicians.
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Objective: The European Society for Clinical and Economic
Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal
Diseases (ESCEO) decided to revisit the 2014 algorithm rec-
ommendations for knee osteoarthritis (OA), using the Grading
of Recommendations Assessment, Development and
Evaluation (GRADE) process.
Material and methods: A Summary of Evidence docu-
ment for each intervention was provided to all members
of a dedicated working group and consisted of: a) 2014
Status; b) 2014–2018 Literature Search Results; c)
GRADE Evidence Profiles: these tables included the sum-
mary of findings and quality assessment by a judgment of
factors that determine the quality of evidence (certainty
assessment) and the magnitude of effect for each
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